These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18620776

  • 1. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
    Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, Iwasa M, Kobayashi Y, Hayashi H, Kaito M, Takei Y.
    J Hepatol; 2008 Nov; 49(5):702-10. PubMed ID: 18620776
    [Abstract] [Full Text] [Related]

  • 2. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
    Kohjima M, Yoshimoto T, Enjoji M, Fukushima N, Fukuizumi K, Nakamura T, Kurokawa M, Fujimori N, Sasaki Y, Shimonaka Y, Murata Y, Koyama S, Kawabe K, Haraguchi K, Sumida Y, Harada N, Kato M, Kotoh K, Nakamuta M.
    World J Gastroenterol; 2015 Mar 21; 21(11):3291-9. PubMed ID: 25805936
    [Abstract] [Full Text] [Related]

  • 3. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.
    Hörl WH, Schmidt A.
    Nephrol Dial Transplant; 2014 Jun 21; 29(6):1141-4. PubMed ID: 24286977
    [Abstract] [Full Text] [Related]

  • 4. Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C.
    Lin TJ, Liao LY, Lin CL, Chang TA, Liu SO.
    Hepatogastroenterology; 2008 Jun 21; 55(85):1412-5. PubMed ID: 18795701
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.
    Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J.
    Hepatology; 2012 Aug 21; 56(2):492-500. PubMed ID: 22334511
    [Abstract] [Full Text] [Related]

  • 6. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, Horiike S, Tanaka H, Iwasa M, Kobayashi Y, Adachi Y, Kaito M.
    J Gastroenterol Hepatol; 2007 Nov 21; 22(11):1886-93. PubMed ID: 17914965
    [Abstract] [Full Text] [Related]

  • 7. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
    Hendy OM, Allam M, Allam A, Attia MH, El Taher S, Eldin MM, Ali A.
    Egypt J Immunol; 2010 Nov 21; 17(2):33-44. PubMed ID: 23082485
    [Abstract] [Full Text] [Related]

  • 8. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP.
    Med Sci Monit; 2010 Mar 21; 16(3):CR137-143. PubMed ID: 20190684
    [Abstract] [Full Text] [Related]

  • 9. Reduced serum hepcidin levels in patients with chronic hepatitis C.
    Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I, Corrocher R, Ganz T, Fattovich G.
    J Hepatol; 2009 Nov 21; 51(5):845-52. PubMed ID: 19729219
    [Abstract] [Full Text] [Related]

  • 10. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.
    J Med Virol; 2013 Sep 21; 85(9):1523-33. PubMed ID: 23775277
    [Abstract] [Full Text] [Related]

  • 11. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
    Inomata S, Anan A, Yamauchi E, Yamauchi R, Kunimoto H, Takata K, Tanaka T, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S.
    Intern Med; 2019 Oct 15; 58(20):2915-2922. PubMed ID: 31243222
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.
    Am J Gastroenterol; 2004 Aug 15; 99(8):1490-6. PubMed ID: 15307866
    [Abstract] [Full Text] [Related]

  • 14. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
    Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y, Kaito M.
    Free Radic Biol Med; 2007 Feb 01; 42(3):353-62. PubMed ID: 17210448
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.
    Rev Invest Clin; 2003 Feb 01; 55(2):138-42. PubMed ID: 12827916
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.